Microbiota γ‐Butyrobetaine Is Associated With Increased Risk of Major Adverse Limb Events in People With Lower Extremity Arterial Disease Undergoing Endovascular Therapy
While both TMAO and γ-butyrobetaine were linked to increased major adverse cardiovascular events in patients with PAD, only γ-butyrobetaine was associated with an elevated risk of MALE.
Authors
- Jiun‐Yang Chiang (ORCID: https://orcid.org/0000-0002-7405-0858)
- Jen‐Kuang Lee (ORCID: https://orcid.org/0000-0003-3790-484X)
- Ming‐Shiang Wu (ORCID: https://orcid.org/0000-0002-1940-6428)
- Wei‐Kai Wu (ORCID: https://orcid.org/0000-0002-9476-8998)
- Zheng‐Wei Chen (ORCID: https://orcid.org/0000-0001-7728-6674)
- Nai‐Chen Cheng (ORCID: https://orcid.org/0000-0003-4071-5628)
Institutions
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1161/jaha.124.037356
- Citations
- 2
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 4.01